Valemetostat Yields Enduring Responses in Relapsed/Refractory PTCL
Phase 2 data support a favorable risk/benefit profile with valemetostat in patients with relapsed/refractory peripheral T-cell lymphoma.
Uterine Transposition May Maintain Fertility Following Pelvic Radiotherapy
Uterine transposition, a surgical approach preserving fertility by moving the uterus out of the radiation field, may improve gynecologic cancer outcomes.
Domvanalimab Combo Improves Survival in Advanced/Metastatic NSCLC
Treatment with domvanalimab/zimberelimab also improved progression-free survival vs platinum-based chemotherapy in the phase 3 ARC-10 study.
Empowering Awareness to Address Rising Gynecological Cancer Incidence
Ginger J. Gardner, MD, FACOG, highlights disease prevention innovations and other ongoing efforts to empower education in the gynecologic cancer field.
Disparities Remain in HCT Use Rates for Minority Groups Despite Growth
Hematologic cell transplantation use rates have improved, although they still show disparities for minority groups such as non-Hispanic Black populations.
FDA Extends Review Period for Zenocutuzumab in NRG1+ PDAC, NSCLC
The updated Prescription Drug User Fee Act date for zenocutuzumab in these indications is February 4, 2025.